ClinicalTrials.gg
Active, not recruitingNCT05399992VICTORION REALUpdated Nov 6, 2026

Study Evaluating LDL-C Change and Adherence to Inclisiran Lipid-lowering Therapy in ASCVD

An observational study in Primary Hypercholesterolemia and Mixed Dyslipidemia, sponsored by Novartis Pharmaceuticals. Active, not recruiting at 40 sites in 8 countries. Open to participants aged 18 Years to 100 Years. Per ClinicalTrials.gov, last updated 2026-11-06.

Primary conditionHypercholesterolemiaRegistry: DyslipidemiasReclassifiedWhy we changed it
Registry
Dyslipidemias — the first condition term the registry derived for this study.
ClinicalTrials.gg
Hypercholesterolemia
Why
  1. The study's listed conditions name Hypercholesterolemia, a narrower term within Dyslipidemias.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by Novartis Pharmaceuticals (part of Novartis) · Observational

Updated Nov 6, 2026Primary completion movedStudy completion moved+2 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
847
Ages
18 Years to 100 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-18

Among 36 studies in Hypercholesterolemia by Novartis — 6 open to participants now, 10 under way, 5 of them phase 3. Hypercholesterolemia · Novartis.

Enrollment
6th of 10
847 · median 1,174
Started
2022
with 3 others
Observational
10 of 36
2 open now
Registered
20th of 36
by date

Among the 36 studies in Hypercholesterolemia by Novartis, this one is the 6th largest by enrollment of the 10 observational ones that give a count, is one of 4 that started in 2022, is one of 10 observational ones, and was the 20th registered.

Hypercholesterolemia

1,177 studies on the registry are indexed under Hypercholesterolemia; 95 are open to participants now.

Browse Hypercholesterolemia studies →

Open to participants now

6 of the 36 studies in Hypercholesterolemia by Novartis are open now, in 12 countries. Recruiting first, the newest first:

1 more — sign in →

By country, each count listing its studies:

All 6 open studies →

Who these studies take

Of the 57 Hypercholesterolemia studies recruiting now, 25 (44%) set no upper age limit and 20 (35%) stop at 75 or younger; 10 take children under 18; 11 take healthy volunteers.

This study: 18 Years to 100 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 36 studies in Hypercholesterolemia by Novartis, or all of them as a file.
02

Study summary

This observational prospective study aims to evaluate the LDL-C change and adherence to inclisiran in combination with other lipid lowering therapies or lipid lowering treatments (LLTs) under conditions of routine clinical practice.

Read the detailed description

Patients will be enrolled over a period of 23 months, and followed for up to 24 months to assess for study outcomes.

03

Conditions studied

  • Primary Hypercholesterolemia
  • Mixed Dyslipidemia

Browse trials for

Keywords

  • primary hypercholesterolemia
  • mixed dyslipidemia
  • real-world study
  • inclisiran
  • lipid-lowering therapy
  • LLT
  • ASCVD
04

In context

Hypercholesterolemia Reclassified

1,177 studies on the registry are indexed under Hypercholesterolemia; 95 are open to participants now.

This study's enrollment of 847 is below the median of 1,000 across 145 observational studies indexed under Hypercholesterolemia.

Browse Hypercholesterolemia studies →

Lead sponsor

Novartis Pharmaceuticals is the lead sponsor of 2,720 studies on the registry; 221 are open to participants now.

Of its 586 completed or terminated interventional studies of FDA-regulated products, 439 (75%) have results posted.

Compared within Hypercholesterolemia, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Dyslipidemias. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

Ages eligible
18 Years to 100 Years
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

The study population will consist of adult participants with an underlying diagnosis of Atherosclerotic Cardiovascular Disease (ASCVD), ASCVD risk equivalent (ASCVD RE), or Heterozygous familial hypercholesterolemia (HeFH) and elevated levels of Low density lipoprotein - Cholesterol (LDL-C)

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Participants who are 18 years or older
  2. Participants with hypercholesterolemia having a diagnosis of ASCVD, ASCVD RE or HeFH
  3. Participants who are not at LDL-C goal as per their CV risk according to respective clinical guidelines
  4. Participants who per physician's criteria need to optimize their LLT
  5. Participants who provide written to participate in the study
  6. Participants who initiate inclisiran under conditions per local label and have LDL-C values available at baseline or within 3 months before treatment initiation.

Exclusion criteria

Exclusion Criteria:

  1. Participants that have received inclisiran previously
  2. Participants participating in a clinical trial with product 3 Participants switching from previous PCSK9 mab treatment (within 90 days prior to Index date)
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

06

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
847 participants (actual)
Patient registry
No

Groups and cohorts

  • Inclisiran cohort

    Participants prescribed inclisiran alone or with other LLTs as per approved label

    Other: Inclisiran

Interventions

  • OtherInclisiran

    Prospective observational study. There is no treatment allocation. Patients who are eligible to receive inclisiran will be enrolled into this study.

07

What researchers measure

Primary outcomes

  1. Percentage change in LDL-C from baseline to 10 months

    Percentage change in Low density lipoprotein - Cholesterol (LDL-C)

    Time frame: Baseline, 10 months

Secondary outcomes

  1. Percentage change in LDL-C from baseline

    Percentage change in LDL-C from baseline is collected

    Time frame: Baseline, month 4, month 16, month 22

  2. Percentage change in LDL-C from baseline by ≥50%

    Percentage change in LDL-C from baseline by ≥50%

    Time frame: Month 4, month 10, month 16, month 22

  3. Percentage change in LDL-C from baseline by ≥30%

    Percentage change in LDL-C from baseline by ≥30%

    Time frame: Month 4, month 10, month 16, month 22

  4. Proportion of participants achieving LDL-C<55 mg/dL

    Proportion of participants achieving LDL-C\<55 mg/dL

    Time frame: Proportion of participants achieving LDL-C<55 mg/dL Month 4, month 10, month 16 and month 22

  5. Proportion of participants achieving LDL-C<70 mg/dL

    Proportion of participants achieving LDL-C\<70 mg/dL

    Time frame: Month 4, month 10, month 16 and month 22

  6. Time-averaged percentage change in LDL-C from baseline

    Time-averaged percentage change in LDL-C from baseline

    Time frame: Baseline, month 4, month 10, month 16 and month 22

  7. Proportion of participants achieving ≥50% reduction in LDL- C at month 10 and maintaining this at 16, 22 and 24 months

    Proportion of participants achieving ≥50% reduction in LDL C at month 10 and maintaining this at 16, 22 and 24 months

    Time frame: Month 10, month 16, month 22 and month 24

  8. Proportion of participants achieving ≥30% reduction in LDL C from baseline to 10 months and maintaining until 24 months

    Proportion of participants achieving ≥30% reduction in LDL C from baseline to 10 months and maintaining until 24 months

    Time frame: Baseline, month 10, month 24

  9. Proportion of participants achieving <55 mg/dL and <70 mg/dL in LDL-C at 10 months and maintaining until 24 months

    Proportion of participants achieving \<55 mg/dL and \<70 mg/dL in LDL-C at 10 months and maintaining until 24 months

    Time frame: Month 10 and month 24

  10. Inclisiran cohort : Percentage of days covered by inclisiran

    Inclisiran cohort : Percentage of days covered by inclisiran

    Time frame: 12 months and 24 months

  11. Inclisiran cohort : Mean PDC

    Mean Proportion of Days Covered (PDC) for inclisiran cohort is collected

    Time frame: 12 months and 24 months

  12. Inclisiran cohort : Proportion of participants with a PDC ≥ 80%

    Proportion of participants with a PDC ≥ 80% (sensitivity: 90%/100%)

    Time frame: 12 months and 24 months

  13. Proportion of participants remaining on initial baseline therapy

    Proportion of patients remaining on initial baseline therapy in the inclisiran cohort

    Time frame: Baseline, month 12 and month 24

  14. Time to discontinuation of any newly initiated therapies

    Time to discontinuation of any newly initiated therapies

    Time frame: Month 12 and month 24

  15. Time to discontinuation of any newly initiated therapies by specific LLT

    Time to discontinuation of any newly initiated therapies by specific LLT

    Time frame: Month 12 and month 24

  16. Change from baseline in scores from the TSQM (modified) instrument

    The 14-item Treatment Satisfaction Questionnaire for Medication (TSQM) version 1.4 is an instrument to assess patients' satisfaction with medication, providing scores on four scales - side effects, effectiveness, convenience and global satisfaction. TSQM V1.4 has a score range of 0 to 100 with with higher scores indicating higher patient satisfaction with medication.

    Time frame: Baseline, month 12 and month 24

  17. Descriptive adherence data based on Adherence AAQ

    Adherence Assessment Questionnaires (AAQ) measures the degree of identified non-adherence to LLT therapy. AAQ has a score range from 0 (not adherent at all) to 100 (absolute adherent).

    Time frame: Month 12 and month 24

  18. Descriptive adherence data based on ABQ

    Adherence Barriers Questionnaire (ABQ) is an instrument for identifying specific barriers to medication-related adherence. ABQ is a descriptive analysis. The number and proportion of patients affected by each barrier will be reported for inclisiran participants.

    Time frame: Month 12 and month 24

08

Study locations

40 sites
  • Novartis Investigative Site
    Feldkirch, 6807, Austria
  • Novartis Investigative Site
    Graz, 8036, Austria
  • Novartis Investigative Site
    Linz, 4021, Austria
  • Novartis Investigative Site
    Sankt Veit im Pongau, 5621, Austria
  • Novartis Investigative Site
    Vienna, 1090, Austria
  • Novartis Investigative Site
    Vienna, 1180, Austria
  • Novartis Investigative Site
    Shenzhen, Guangdong 518000, China
  • Novartis Investigative Site
    Holon, Gush Dan 5845997, Israel
  • Novartis Investigative Site
    Petah Tikva, 4941492, Israel
  • Novartis Investigative Site
    Tel Aviv, 6801296, Israel
  • Novartis Investigative Site
    Kuala Lumpur, Kuala Lumpur 50470, Malaysia
  • Novartis Investigative Site
    Kuala Lumpur, 50400, Malaysia
  • Novartis Investigative Site
    Riyadh, Saudi 11643, Saudi Arabia
  • Novartis Investigative Site
    Jeddah, 23311, Saudi Arabia
  • Novartis Investigative Site
    Tabuk, 47512, Saudi Arabia
  • Novartis Investigative Site
    Fribourg, CH 1708, Switzerland
  • Novartis Investigative Site
    Basel, 4031, Switzerland
  • Novartis Investigative Site
    Geneva, 1211, Switzerland
  • Novartis Investigative Site
    Lausanne, 1011, Switzerland
  • Novartis Investigative Site
    Olten, 4600, Switzerland
  • Novartis Investigative Site
    Sankt Gallen, 9007, Switzerland
  • Novartis Investigative Site
    Zurich, 8032, Switzerland
  • Novartis Investigative Site
    Zurich, 8091, Switzerland
  • Novartis Investigative Site
    Abu Dhabi, 00000, United Arab Emirates
  • Novartis Investigative Site
    Abu Dhabi, United Arab Emirates
  • Novartis Investigative Site
    Al Ain City, United Arab Emirates
  • Novartis Investigative Site
    Dubai, 000000, United Arab Emirates
  • Novartis Investigative Site
    Dubai, United Arab Emirates
  • Novartis Investigative Site
    High Wycombe, Buckinghamshire HP11 2TR, United Kingdom
  • Novartis Investigative Site
    Louth, Lincolnshire LN11 7QU, United Kingdom
  • Novartis Investigative Site
    Portadown, Nothern Ireland BT63 5QQ, United Kingdom
  • Novartis Investigative Site
    Sunderland, Tyne and Wear SR4 7TP, United Kingdom
  • Novartis Investigative Site
    Belfast, BT16 1RH, United Kingdom
  • Novartis Investigative Site
    Bromwich, B71 4HJ, United Kingdom
  • Novartis Investigative Site
    Burton-on-Trent, DE13 0RB, United Kingdom
  • Novartis Investigative Site
    Hull, HU3 2RW, United Kingdom
  • Novartis Investigative Site
    Lancaster, LA1 4RP, United Kingdom
  • Novartis Investigative Site
    Liverpool, L7 8XP, United Kingdom
  • Novartis Investigative Site
    London, NW3 2QG, United Kingdom
  • Novartis Investigative Site
    Middlesex, UB9 6JH, United Kingdom
09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Sep 2022 (actual). Primary completion is estimated for Nov 2026, 50 months after the start.

Of 51 observational studies under Hypercholesterolemia, half reached primary completion within 33 months of starting (the median), counting those still running; a quarter within 22 and three quarters within 59. This study's planned 50 months is above that.

Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 6, 2026: primary completion Oct 2026 → Nov 2026 and completion Oct 2026 → Nov 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
May 27, 2022
First posted
Jun 1, 2022
StartActual
Sep 12, 2022
Primary completionEst.
Nov 23, 2026was Oct 2026
CompletionEst.
Nov 23, 2026was Oct 2026
Last update
Nov 6, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
3 sites added, 1 site removed
Show 3 added (2 United Arab Emirates, 1 United Kingdom)
  • Novartis Investigative Site · Abu Dhabi, United Arab Emirates
  • Novartis Investigative Site · Dubai, United Arab Emirates
  • Novartis Investigative Site · Portadown, United Kingdom
Show 1 removed
  • Novartis Investigative Site · Dubai, United Arab Emirates
Nov 6, 2026
Primary completion
Oct 5, 2026→Nov 23, 2026
Nov 6, 2026
Study completion
Oct 5, 2026→Nov 23, 2026
Nov 6, 2026
Show all 1 update
  1. Nov 6, 2026
    3 sites added, 1 site removed
    Show 3 added (2 United Arab Emirates, 1 United Kingdom)
    • Novartis Investigative Site · Abu Dhabi, United Arab Emirates
    • Novartis Investigative Site · Dubai, United Arab Emirates
    • Novartis Investigative Site · Portadown, United Kingdom
    Show 1 removed
    • Novartis Investigative Site · Dubai, United Arab Emirates
    Primary completion Oct 5, 2026→Nov 23, 2026
    Study completion Oct 5, 2026→Nov 23, 2026
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT05399992
Responsible party
Sponsor
First posted
Jun 1, 2022
Start date
Sep 12, 2022
Primary completion
Nov 23, 2026 (estimated)
Completion
Nov 23, 2026 (estimated)
Last update
Nov 6, 2026

Study contacts

Novartis Pharmaceuticals
study director · Novartis Pharmaceuticals
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion